119 related articles for article (PubMed ID: 10720779)
1. Transgenic mouse models in carcinogenesis research and testing.
Thorgeirsson SS; Factor VM; Snyderwine EG
Toxicol Lett; 2000 Mar; 112-113():553-5. PubMed ID: 10720779
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenicity and mutagenicity of heterocyclic amines in transgenic mouse models.
Thorgeirsson SS; Ryu DY; Weidner V; Snyderwine EG
Cancer Lett; 1999 Sep; 143(2):245-7. PubMed ID: 10503912
[TBL] [Abstract][Full Text] [Related]
3. Hepatic tumor induction in c-myc mono-transgenic and TGF-alpha/c-myc double-transgenic mice.
Thorgeirsson SS; Santoni-Rugiu E; Davis CD; Snyderwine EG
Arch Toxicol Suppl; 1997; 19():359-66. PubMed ID: 9079223
[TBL] [Abstract][Full Text] [Related]
4. Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis.
Thorgeirsson SS; Santoni-Rugiu E
Br J Clin Pharmacol; 1996 Jul; 42(1):43-52. PubMed ID: 8807143
[TBL] [Abstract][Full Text] [Related]
5. Interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis.
Thorgeirsson SS; Santoni-Rugiu E
Mutat Res; 1997 May; 376(1-2):221-34. PubMed ID: 9202759
[TBL] [Abstract][Full Text] [Related]
6. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis.
Factor VM; Kiss A; Woitach JT; Wirth PJ; Thorgeirsson SS
J Biol Chem; 1998 Jun; 273(25):15846-53. PubMed ID: 9624185
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.
Murakami H; Sanderson ND; Nagy P; Marino PA; Merlino G; Thorgeirsson SS
Cancer Res; 1993 Apr; 53(8):1719-23. PubMed ID: 8467484
[TBL] [Abstract][Full Text] [Related]
8. In vivo mutagenicity and hepatocarcinogenicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in bitransgenic c-myc/lambda lacZ mice.
Ryu DY; Pratt VS; Davis CD; Schut HA; Snyderwine EG
Cancer Res; 1999 Jun; 59(11):2587-92. PubMed ID: 10363978
[TBL] [Abstract][Full Text] [Related]
9. Molecular analyses of liver tumors in c-myc transgenic mice and c-myc and TGF-alpha double transgenic mice.
Ohgaki H; Sanderson ND; Ton P; Thorgeirsson SS
Cancer Lett; 1996 Aug; 106(1):43-9. PubMed ID: 8827045
[TBL] [Abstract][Full Text] [Related]
10. In vivo mutagenicity and DNA adduct levels of heterocyclic amines in Muta mice and c-myc/lacZ double transgenic mice.
Davis CD; Dacquel EJ; Schut HA; Thorgeirsson SS; Snyderwine EG
Mutat Res; 1996 Sep; 356(2):287-96. PubMed ID: 8841498
[TBL] [Abstract][Full Text] [Related]
11. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer.
Calvisi DF; Thorgeirsson SS
Toxicol Pathol; 2005; 33(1):181-4. PubMed ID: 15805070
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.
Santoni-Rugiu E; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1999 Jun; 154(6):1693-700. PubMed ID: 10362794
[TBL] [Abstract][Full Text] [Related]
14. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.
Calvisi DF; Factor VM; Loi R; Thorgeirsson SS
Cancer Res; 2001 Mar; 61(5):2085-91. PubMed ID: 11280770
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
16. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes.
Sargent LM; Sanderson ND; Thorgeirsson SS
Cancer Res; 1996 May; 56(9):2137-42. PubMed ID: 8616862
[TBL] [Abstract][Full Text] [Related]
17. Promotion of hepatocarcinogenesis by phenobarbital in c-myc/TGF-alpha transgenic mice.
Sanders S; Thorgeirsson SS
Mol Carcinog; 2000 Jul; 28(3):168-73. PubMed ID: 10942533
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer.
Calvisi DF; Ladu S; Hironaka K; Factor VM; Thorgeirsson SS
J Hepatol; 2004 Nov; 41(5):815-22. PubMed ID: 15519655
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
20. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
